Tavalisse

AML

Pharma

Rigel's nod for Rezlidhia sets up battle with Servier in AML

Rigel has won approval for Rezlidhia for adults with relapsed or refractory acute myeloid leukemia with the IDH1 genetic mutation.

Kevin Dunleavy Dec 2, 2022 9:57am

Grifols

Grifols opens plant, snags NICE nod for Tavlesse

Oct 19, 2022 10:15am

Tavalisse

Rigel snags first FDA win with Tavalisse OK

Apr 18, 2018 9:52am